Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naive Populations from a Phase 2b Open-Label Extension Study

Mease P, Deodhar A, Merola J, Mcinnes I, Assudani D, Bajracharya R, Coarse J, Ink B, Schett G (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Arthritis and Rheumatology Wiley

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 2782-2785

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

University of Glasgow GB United Kingdom (GB) UCB Pharma Ltd GB United Kingdom (GB) Swedish Medical Center US United States (USA) (US) Oregon Health and Science University (OSHU) US United States (USA) (US) Harvard University US United States (USA) (US)

How to cite

APA:

Mease, P., Deodhar, A., Merola, J., Mcinnes, I., Assudani, D., Bajracharya, R.,... Schett, G. (2021). Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naive Populations from a Phase 2b Open-Label Extension Study. In ARTHRITIS & RHEUMATOLOGY (pp. 2782-2785). HOBOKEN: WILEY.

MLA:

Mease, Philip, et al. "Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naive Populations from a Phase 2b Open-Label Extension Study." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2021. 2782-2785.

BibTeX: Download